Syndax Pharmaceuticals SNDX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's net income?
- Syndax Pharmaceuticals (SNDX) reported net income of -$42.67M in Q1 2026.
- How has Syndax Pharmaceuticals's net income changed year-over-year?
- Syndax Pharmaceuticals's net income increased by 49.7% year-over-year, from -$84.85M to -$42.67M.
- What is the long-term trend for Syndax Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's net income has grown at a 84.0% compound annual growth rate (CAGR), from $24.93M to -$285.42M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.